RELATED ATTORNEYS
Mark Schuman represented Teva in support of its efforts to introduce a generic version of Zantac® (ranitidine) oral solution despite Glaxo’s charges of patent infringement. After a motion for summary judgment was filed, the case settled favorably for the client.